- tylvinblastine-3-oic acid in biological fluids. *J Chromatogr* 1991;553:47-53.
- van Tellingen O, Beijnen JH, Nooijen WJ. Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature. *J Pharm Biomed Anal* 1991; 9:1077-82.
 - Oosterkamp HM, Vlasveld LT, Wanders J, Beijnen JH, van Tellingen O, Dubbelman AC, et al. Phase I study of vinorelbine, a tryptophan ester of vinblastine. *Eur J Cancer* 1991;27: 1222-6.
 - van Tellingen O, Kuijpers AV, Beijnen JH, Baselier MRP, Burghouts JTM, Nooijen WJ. Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection. *J Chromatogr* 1992;573:328-32.
 - van Tellingen O, Beijnen JH, Baurain R, ten Bokkel Huinink WW, van der Woude HR, Nooijen WJ. Biodetermination of *N*-(deacetyl-O-4-vinblastoyl-23)-L tryptophan, a metabolite of vinorelbine, by high-performance liquid chromatography with fluorescence detection. *J Chromatogr* 1992;574:293-8.
 - van Tellingen O, Beijnen JH, Nooijen WJ, Bult A. Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review). *Anticancer Res* 1992;12:1699-715.
 - van Tellingen O, Beijnen JH, Nooijen WJ, Bult A. Plasma pharmacokinetics of vinorelbine and the investigational vinca alkaloid *N*-(deacetyl-O-4-vinblastoyl-23)-L isoleucinate in mice as determined by high-performance liquid chromatography. *Cancer Res* 1993;53:2061-5.
 - van Tellingen O, Beijnen JH, Nooijen WJ, Bult A. Plasma pharmacokinetics, disposition excretion and metabolism of vinorelbine in mice as determined by high-performance liquid chromatography. *Cancer Chemother Pharmacol* 1993;32: 286-92.
 - van Tellingen O, Kuijpers AV, Beijnen JH, Nooijen WJ, Bult A. Plasma pharmacokinetics, disposition excretion and metabolism of vinorelbine in mice as determined by high-performance liquid chromatography. *Invest New Drugs* 1993;11: 141-50.
 - van Tellingen O, Sonneveldt ALC, Beijnen JH, Nooijen WJ, Kettenes-van den Bosch JJ, Versluis C, et al. Plasma pharmacokinetics, disposition excretion and metabolism of vinorelbine in mice as determined by high-performance liquid chromatography. *Cancer Chemother Pharmacol* 1994;33: 423-34.

Purine and pyrimidine metabolism: still a black box?

• G.J. Peters and J.H. Beijnen

Pharm World Sci 1994;16(2):37-8

The Editorial in the Special Issue on Purine and Pyrimidine Metabolism contained some inaccuracies. In the right-hand column on page 38, the fourth line from the top should have mentioned 'small black (and sometimes grey) boxes'. The generic name of 'arabinosyl-cytosine' (Table 1) is *cytarabine*.

Purine metabolism in the heart

Strategies for protection

against myocardial ischaemia

• Kris Ver Donck

Pharm World Sci 1994;16(2):69-76

In the paragraph *Compounds* (page 71) it was not quite clear that draflazine is identical with the *L*-enantiomer of R 75 231. The last sentence of the paragraph *Cardiac function* (page 72) should have read 'In contrast, none of the six control animals in this experiment could be weaned from cardiopulmonary bypass.' The correct page numbers for reference 21 are 1499-509.

Role of differentiation induction in action of purine antimetabolites

• George Weber, Yuki Hata and Noemi Prajda

Pharm World Sci 1994;16(2):77-83

In the abstract, 'difluorodeoxycytidine' should have been replaced by its generic name, *gemcitabine*. In Table 2, the abbreviations in the *Cytogenetics* column indicate the following: inv: inversion; +: gain; t: translocation; der: derivative chromosome; i: inversion; q: long arm of chromosome; del: deletion. Reference 17 has now been published: *Oncol Res* 1993;5:161-4.

On the contents page, the title of this paper was incorrect.